Abdominoperineal resection does not decrease quality of life in patients with low rectal cancer by Campos-Lobato, Luiz Felipe de et al.
CLINICAL SCIENCE
Abdominoperineal resection does not decrease
quality of life in patients with low rectal cancer
Luiz Felipe de Campos-Lobato, Patricia Cristina Alves–Ferreira, Ian C. Lavery, Ravi P Kiran
Department of Colorectal Surgery, Digestive Disease Institute, Cleveland Clinic, Cleveland, OH.
PURPOSE: Issues related to body image and a permanent stoma after abdominoperineal resection may decrease
quality of life in rectal cancer patients. However, specific problems associated with a low anastomosis may similarly
affect quality of life for patients undergoing low anterior resection. The aim of this study was to compare quality of
life of low rectal cancer patients after undergoing abdominoperineal resection versus low anterior resection.
METHODS: Demographics, tumor and treatment characteristics, and prospectively collected preoperative quality-of-
life data for patients undergoing low anterior resection or abdominoperineal resection for low rectal cancer
between 1995 and 2009 were compared. Quality of life collected at specific time intervals was compared for the two
groups, adjusting for age, body mass index, use of chemoradiation, and 30 days postoperative complications. The
short-form-36 questionnaire was used to determine quality of life.
RESULTS: The query returned 153 patients (abdominoperineal resection = 68, low anterior resection = 85) with a
median follow-up of 24 (3-64) mo. The after abdominoperineal resection group had a higher mean age (63¡ 12 vs.
54 ¡ 12, p , 0.001) and more American Society of Anesthesiologists classification 3/4 patients (65 percent vs. 43
percent, p = 0.03) than low anterior resection. Other demographics, tumor stage, use of chemoradiation, overall
postoperative complication rates, and quality-of-life follow-up time were not statistically different in both groups.
Patients undergoing abdominoperineal resection had a lower baseline short-form-36 mental component score than
those undergoing low anterior resection. However, 6 mo after surgery this difference was no longer statistically
significant and essentially disappeared at 36 mo after surgery.
CONCLUSION: Patients undergoing abdominoperineal resection for low rectal cancer have a similar long-term
quality of life as those undergoing low anterior resection. These findings can help clinicians to better counsel
patients with low rectal cancer who are being considered for abdominoperineal resection.
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INTRODUCTION
An increasing number of people are diagnosed with rectal
cancer in the United States each year, with approximately
50,000 new cases expected for the year 2010.1 The past two
decades have been marked by advances in rectal cancer
treatment, particularly the widespread adoption of total
mesorectal excision2-4 and use of neoadjuvant chemoradia-
tion,5,6 both of which have improved local control, whereas
modern adjuvant chemotherapy regimens have increased
overall and disease-free survival.7-9 Therefore, gaining a better
understanding of the quality of life (QOL) of rectal cancer
survivors has become a matter of paramount importance.
The surgical treatment options for patients with low rectal
cancer (i.e., less than 5 cm from the anal verge) include low
anterior resection (LAR) or abdominoperineal resection
(APR).9-11 An APR is the procedure of choice when a distal
margin of clearance cannot be obtained or the sphincter
complex is invaded by the tumor, whereas LAR is indicated
for all other low rectal cancers10,12,13 or LAR is technically
feasible butmay be associatedwith poor functional outcomes
because of sphincter dysfunction. It is a common perception
that issues related to body image and a permanent stoma
after APR have a negative impact on QOL; consequently, this
procedure is avoided whenever possible.14 Recent studies
have shown, however, that specific problems associated with
a low anastomosis may similarly affect QOL of patients with
low rectal cancer who undergo LAR.15,16 Therefore, the aim
of this study is to compare the overall QOL in low rectal
cancer patients undergoing either APR or LAR.
PATIENTS AND METHODS
This study was approved by the Cleveland Clinic
Institutional Review Board. A single center, prospectively
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maintained, colorectal cancer database was queried for
patients with low rectal cancer who underwent curative
intent APR or LAR between January 1, 1995, and January 1,
2009. Low rectal cancer was defined as cancer where the
tumor was located no more than 5 cm from the anal verge,
as detected by rigid proctoscopy. Only patients with
documented preoperative overall QOL assessment were
included.
APR and LAR patients were compared with respect to
demographics, preoperative morbidity, treatment character-
istics, tumor stage, and overall QOL. Overall QOL was
assessed through the validated short-form 36 questionnaire
(SF-36), given up to 30 days prior to surgery, then at 6-, 12-,
and 36-mo intervals postoperatively.
SF-36, a widely used QOL questionnaire, includes 36
items selected from a larger pool of items originally used in
the RAND Coorporation’s Medical Outcomes Study.17
Using multi-item scales of 35 items, it assesses eight health
concepts as follows:
1. Physical functioning (10 items)
2. Role limitations caused by physical health problems (3
items)
3. Role limitations caused by emotional problems (3 items)
4. Social functioning (2 items)
5. Emotional well-being (5 items)
6. Energy/fatigue (4 items)
7. Pain (2 items)
8. General health perceptions (5 items)
A final item assesses the patient’s perception of changes
in health status over the last 12 mo.
In order to ensure the honesty and accuracy of patient
answers, patients were given the opportunity to fill out the
preoperative questionnaire privately in the clinic or to take
the questionnaires home with them, to complete and return
by mail before the date of their surgery. The follow-up
questionnaires were mailed to the patients’ homes, for them
to complete at their convenience.
Statistical analysis
Categorical variables were expressed as numbers and
percentages and compared with Pearson x2 and Fischer’s
exact tests. Parametirc data were expressed as mean and
standard deviation with the Student t-test for comparison.
Nonparametric data were depicted as medians and inter-
quartile ranges and compared with the Wilcoxon rank sum
test. The overall QOL of APR versus LAR patients was
compared with an analysis of covariance, adjusting for age
at surgery, body mass index (BMI), chemoradiation use, and
30 days postoperative complications.
RESULTS
Pretreatment characteristics
The database query returned 606 patients. Preoperative
QOL assessment responses were available for 153 patients,
and only these patients were hence included in this study.
Sixty eight (44 percent) patients underwent APR and 85 (56
percent) patients underwent LAR. Five of the 85 LAR
operations were intersphinteric resections. The median age
was 57 y (interquartile range 49-67), and 49 (32 percent)
patients were female. The proportion of patients with
American Society of Anesthesiologists (ASA) classification
3 or 4 was significantly higher in the APR group (45
patients, 65 percent) than in the LAR group (36 patients, 43
percent), p = 0.04. The median age of patients undergoing
APR (63 y, interquartile range 54-74) was also significantly
higher than those undergoing LAR (55 y, interquartile range
45-61), p , 0.001. Other demographics and preoperative
morbidity were not significantly different between the two
groups.
As expected, the median tumor distance from anal verge
was significantly shorter in APR (3 cm, interquartile range
2-4) than in LAR patients (4 cm, interquartile range 3-5), p ,
0.01. All patients undergoing LAR also underwent a
diverting stoma creation. Only 6 out of 85 LAR patients
still had a diverting loop ileostomy at 6 mo after the index
procedure, and 3 out of these received adjuvant chemother-
apy.
There were 8 patients (19 percent) with a pretreatment
stage (c-stage) I, 22 patients (52 percent) with a c-stage II, 7
patients (17 percent) with a c-stage III, and 5 patients (12
percent) with a c-stage IV. C-stage dispersion was not
significantly different between the two groups (Table 1).
Radiotherapy and pathologic stage
A total of 114 patients (74 percent) underwent radiation
treatment, with 108 patients (95 percent) undergoing
radiation before surgery. The proportion of patients receiv-
ing preoperative radiation treatment was significantly
higher in the LAR group (67 patients, 79 percent) than in
the APR group (41 patients, 60 percent), p = 0.02. However,
the use of postoperative radiation was higher in patients
undergoing APR (5 patients, 7 percent) than in those
undergoing LAR (1 patient, 1 percent); this was, however,
not statistically significant (p = 0.06).
A total of 17 patients (13 percent) had pathologic
complete response: 2 patients (5 percent) in the APR group
and 15 patients (4 percent) in the LAR group, p = 0.02.
Twelve (8 percent) patients were pathologic stage (p-stage)
I, 33 patients (22 percent) p-stage II, 45 patients (29 percent)
p-stage III, and 8 patients (5 percent) p-stage IV. Excluding
patients with pathologic complete response, the p-stages
Table 1 - Pretreatment characteristics.
Variables APR 68 (44%) LAR 85 (56%) p Value
Age (years) 63 (54-74) 55 (45-61) ,0.001
Gender (Female) 26 (38) 23 (27) 0.14
BMI kg/m2 28 (24-32) 26 (23-30) 0.11
ASA
1 1 (1) 1 (1) 0.04
2 23 (34) 48 (56)
3 42 (62) 35 (41)
4 2 (3) 1 (2)
DAV (cm) 3 (2-4) 4 (3-5) ,0.001
Clinical stage 0.17
I 13 (19) 16 (19)
II 39 (57) 41 (48)
III 7 (10) 20 (24)
IV 9 (14) 8 (9)
Continuous variables expressed as medians and interquartile ranges.
Nominal variables expressed as absolute numbers with percentages in
parenthesis.
APR: Abdominoperienal resection, LAR: Low anterior resection, BMI: Body
mass index, ASA: American Society of Anesthesiologists classification,
DAV: Distance from anal verge.
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were not significantly different between LAR and APR
patients (Table 2).
Postoperative complications
Table 3 outlines the 30 d postoperative complications.
Except for urinary retention, which was more common
among patients undergoing APR, all other complications
rates were not significantly different between the two
surgical groups.
Overall QOL
Table 4 demonstrates the SF-36 physical (pSF-36) and
mental (mSF-36) components scores.
Physical component
In the unadjusted analysis, patients undergoing APR had
a trend to a lower pSF-36 score at baseline and 36 mo after
surgery than those undergoing LAR. However, these
differences could not be observed when the analysis was
adjusted for age at surgery, BMI, pathologic stage, use of
radiation therapy, and 30 days postoperative complications.
Mental component
The mean baseline mSF-36 score was significantly lower
in patients undergoing APR (43.56 ¡ 10.05) than in those
undergoing LAR (48.54 ¡ 9.73), p = 0.003. However, this
difference could not be observed at the 6-, 12-, and 36-mo
postoperative follow-up intervals.
Changes in overall QOL
The changes in the pSF-36 were not significantly different
between the two groups during the entire follow-up period.
Patients undergoing APR positively changed the mean mSF-
36 score in every follow-up period, whereas LAR patients
actually decreased their mean mSF-36 score during the
follow-up period. (Table 5).
DISCUSSION
This study was designed to compare the overall QOL of
patients with low rectal cancer undergoing APR vs. LAR.
Our results demonstrate that patients undergoing APR have
lower mSF-36 and pSF-36 scores at baseline when compared
with patients who undergo LAR. However, in the post-
operative period, patients undergoing APR tend to have
improvement in SF-36 scores, such that at 6 mo after surgery
the overall QOL difference between LAR and APR is
no longer statistically significant. This difference further
decreases and essentially disappears at the 36-mo post-
operative period.
The QOL differences between patients undergoing APR
and LAR have been studied in the past;18 however, many of
these studies did not use validated tools to assess QOL,19-21
included patients without a baseline QOL assessment,22-24
did not adjust the analysis for confounding factors such as
age, gender, and tumor staging,19,22 or also included
patients with upper-third rectal cancers.22,25 A 2005
Cochrane review26 regarding the QOL of rectal cancer
patients undergoing LAR and APR evaluated a sample of
1,412 from 25 studies. The authors concluded that the
studies reviewed did not confirm any conclusions about the
QOL of patients undergoing APR being inferior or superior
to that of patients who underwent LAR and opined that
better designed studies with larger samples are required.
The main drawbacks cited by the review were the absence
of baseline QOL assessment, inclusion of mid- and upper-
third rectal cancers, short follow-up and missing data, and
finally no data regarding patient social class.
In an attempt to overcome these limitations of the
previous studies, we included only low rectal cancer
patients who had the overall QOL assessed prior to surgery.
Moreover, we evaluated the overall QOL using the SF-36, a
tested and validated measure of health status that was
developed in the United States and that is currently
validated for use in 13 countries.27,28 Finally, we also
adjusted the overall QOL to decrease the effect of potentially
confounding factors, thus effectively placing more emphasis
on the treatment paradigm, that is, APR or LAR.
The fact that patients who underwent APR have a similar
long-term QOL to those who underwent LAR is an apparent
contradiction to traditional beliefs.14 An APR is without a
doubt a much greater mutilation than an LAR and also has a
potentially major impact on body image.29 However, LAR
has been associated with side effects that can drastically
decrease overall postoperative QOL, including fecal incon-
tinence, urgency and outlet dysfunction, as well as those
complications typical of any anastomosis, such as strictures,
and leaks.30-33
The realization that a permanent ostomy is inevitable in
an attempt to defeat their cancer is likely responsible for the
lower QOL at baseline for the APR patients, because this
Table 2 - Radiation therapy and pathologic stage.
Variables APR 68 (44%) LAR 85 (56%) p Value
Preoperative radiation 41 (60) 67 (79) 0.02
Postoperative radiation 5 (7) 1 (1) 0.06
Pathologic complete
response
2 (3) 15 (18)
0.02
Pathologic stage 0.5
I 20 (29) 30 (35)
II 18 (26) 15 (18)
III 24 (35) 21 (24)
IV 4 (6) 4 (5)
Nominal variables expressed as absolute numbers with percentage in
parenthesis.
APR: Abdominoperineal resection, LAR: Low anterior resection.
Table 3 - Postoperative complications.
Variables APR 68 (44%) LAR 85 (56%) p Value
Urinary infection 1 (2) 3 (4) 0.63
Urinary
retention
8 (12) 2 (2) 0.02
Wound infection 2 (3) 3 (4) 1
Wound
dehiscence
2 (3) 1 (1) 0.59
Abd/Pelvic
Abscess
4 (6) 5 (6) 1
Perineal
infection
9 (13) N/A N/A
Anastomotic
leak
N/A 7 (8) N/A
Reoperation 2 (3) 5 (6) 0.46
Readmission 9 (13) 4 (5) 0.07
Nominal variables expressed as absolute numbers with percentage in
parenthesis.
APR: Abdominoperineal resection, LAR: Low anterior resection, Abd:
Abdominal, N/A: Not applicable.
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was obtained in the preoperative period. A further
corroboration of this premise is the finding that the mSF-
36 score was lower for APR rather than LAR patients,
although the pSF-36 score was similar between groups. In
contrast, the hope that LAR carries, of avoiding a permanent
stoma, may lead to patients being more hopeful and positive
prior to surgery, as depicted by the higher baseline mSF-36
score. Thus LAR patients may carry a higher expectation for
surgical outcomes than APR patients. However, LAR may
be associated with multiple side effects as discussed, which
may affect QOL after surgery, regardless of how well
patients have been counseled about these factors by their
surgeons. As a result, when LAR patients are in the midst of
having to adapt to their new lifestyle governed by bowel
function, the potential for frustration can be great, because it
may contradict these expectations. On the other hand,
patients undergoing APR typically have a lower preopera-
tive expectation, and, following the realization that they can
lead a fairly normal life despite coping with a stoma, they
may become more satisfied on average, postoperatively.
This is further supported by the fact that, in our study, the
major changes in overall QOL happened in the mSF-36, with
LAR patients decreasing their mSF-36 scores throughout the
follow-up period, whereas that of APR patients increased.
The confidence intervals for mean differences between the
groups presented in Tables 4 and 5 have lower and upper
Table 4 - Overall quality of life.
SF-36 component APR 68 (44%) LAR 85 (56%) Nonadjusted analysis Adjusted analysis
b
Difference in meansa (95% CI) p Value Difference in meansa (95% CI) p Value
Physical
Baseline
44.8 ¡ 9.2
N = 68
47.7 ¡ 8.8
N = 85
+2.9 (+0.03 to +5.85) 0.05 +1.7 (-1.6 to +5.0) 0.32
6 mo
43.6 ¡ 10.0
N = 25
46.14 ¡ 8.3
N = 48
+2.5 (-1.8 to +6.8) 0.26 +1.6 (-2.8 to +6.1) 0.48
12 mo
46.3 ¡ 10.6
N = 30
48.3 ¡ 7.7
N = 55
+2.0 (-1.9 to +5.9) 0.33 +1.3 (-3.1 to +5.6) 0.56
36 mo
45.2 ¡ 11.3
N = 25
50.5 ¡ 9.2
N = 29
+5.3 (-0.2 to +10.8) 0.06 +6.6 (-1.0 to +12.2) 0.22
Mental
Baseline
43.6 ¡ 10.1
N = 68
48.5 ¡ 9.7
N = 85
+5.0 (+1.8 to +8.2) 0.003 +5.6 (+1.9 to +9.3) 0.003
6 mo
46.4 ¡ 10.4
N = 25
46.3 ¡ 9.0
N = 48
-0.1 (-4.6 to +4.5) 0.98 -0.3 (-5.3 to +4.8) 0.92
12 mo
48.0 ¡ 9.8
N = 30
47.6 ¡ 9.0
N = 55
-0.5 (-4.6 to +3.7) 0.83 +0.14 (-4.5 to +4.8) 0.95
36 mo
47.4 ¡ 10.0
N = 25
49.9 ¡ 8.1
N = 29
+2.5 (-2.4 to +7.3) 0.32 +2.8 (-2.4 to +7.9) 0.29
Values expressed as means and standard deviation. SF-36: Short form. A complete quality of life follow-up could not be obtained for a portion of patients
involved in this study.
APR: Abdominoperienal resection, LAR: Low anterior resection, CI: Confidence interval. a Calculated by subtracting the mean SF-36 score of APR from LAR
at the time of the assessment. b Analysis adjusted for age at surgery, body mass index, pathologic stage, use of radiation therapy, and 30 d postoperative
complications.
Table 5 - Changes in overall quality of life.
SF-36 component APR 68 (44%) LAR 85 (56%) Nonadjusted analysis Adjusted analysis
b
Difference in meansa (95%
CI) p - Value Difference in meansa (95% CI) p Value
Physical
6 mo
21.7 ¡ 11.6
N = 25
22.0 ¡ 9.5
N = 48
20.4 (25.4 to +4.6) 0.88 +0.4 (25.1 to +5.9) 0.89
12 mo
1.0 ¡ 8.7
N = 30
21.12 ¡ 9.7
N = 55
22.2 (26.4 to +2.1) 0.32 21.3 (25.9 to +3.3) 0.58
36 mo
22.2 ¡ 11.9
N = 25
20.6 ¡ 9.5
N = 29
+1.7 (24.1 to +7.4) 0.57 +3.2 (23.1 to +9.4) 0.33
Mental
6 mo
0.6 ¡ 10.0
N = 25
22.5 ¡ 11.4
N = 48
23.1 (28.4 to +2.2) 0.26 23.1 (29.1 to +2.9) 0.31
12 mo
4.4 ¡ 11.0
N = 30
22.5 ¡ 10.3
N = 55
26.9 (211.7 to +2.2) 0.005 27.9 (213.1 to +2.6) 0.004
36 mo
2.5 ¡ 11.2
N = 25
21.5 ¡ 11.1
N = 29
24.0 (210.0 to +2.0) 0.2 24.2 (210.7 to +2.3) 0.21
Values expressed as means and standard deviation. SF-36: Short form, APR: Abdominoperienal resection, LAR: Low anterior resection, CI: Confidence
interval.
A complete quality of life (QOL) follow-up could not be obtained for a portion of patients involved in this study. Changes in QOL calculated by
subtracting the mean SF-36 score from the baseline mean SF-36 score. a Calculated by subtracting the changes in SF-36 score of LAR from change in SF-36
score of APR patients. b Analysis adjusted for age at surgery, pathologic stage, use of radiation therapy,and 30 d postoperative complications.
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limits with absolute values that typically do not exceed 10
points, and at most are as high as 13.1 points. McHorney
and Tarlov34 estimated that a 13-point change in an SF-36
score would be necessary to generate a clinically significant
change. Using a 13-point criterion, one would conclude,
based on our confidence interval results, that the SF-36
outcomes in the APR and LAR groups are practically
equivalent.
Our study suffers from the limitations of a retrospective
review. In order to more accurately assess changes in QOL
after surgery, only those patients who had completed the
preoperative QOL questionnaire were included. Therefore,
one could argue that our study cohort may not be
representative of the experience of all patients who under-
went surgery within our department during the study
period. In order to minimize this potential limitation, we
compared the demographics, tumor and treatment char-
acteristics, and oncologic outcomes of the patients included
in the study with those who were excluded. No statistically
significant difference could be found between the two
groups, suggesting that the study group likely had
characteristics similar to the entire population.
In the face of several statistically nonsignificant results as
they relate to QOL comparison, one could argue whether
our study has sufficient evidence to suggest that the
outcomes for the APR and LAR groups are similar. The
confidence intervals for mean differences between the
groups presented in Tables 4 and 5 have absolute values
that, with few exceptions, do not exceed 10 points and have
an upper limit of 13.1 points. McHorney and Tarlov34
estimated that a 13-point change in an SF-36 score would
be necessary to generate a clinically significant change.
Therefore, using a 13-point criterion, one would conclude
that, based upon our confidence interval results, the SF-36
outcomes in the APR and LAR groups are essentially
equivalent.
Although all patients had a baseline QOL assessment, this
assessment did not take place for every patient at all of the
follow-up periods. As a result, different samples were
formed in each period. Also, we could not evaluate other
factors affecting QOL, such as urinary and sexual function.
Moreover, excluding patients without baseline QOL assess-
ment might have created a unique sample that could not
retract the reality. Because QOL is likely associated with
multiple other factors35 these results may be confounded by
such factors. In order to circumvent this possibility, we
adjusted our analysis for the following factors that might
influence QOL: age at surgery,36 BMI,37 pathologic stage,26
use of radiation therapy,38 and 30 d postoperative complica-
tions.39
The results of this study that evaluated preoperative and
follow-up SF-36 over a prolonged postoperative period for a
large cohort of patients are likely a reflection of general QOL
of patients undergoing the two operations. Irrespective of
the reasons for the results, the finding that patients
undergoing APR for low rectal cancer have long-term
QOL similar to those undergoing restorative resection is
likely to have implications for practice. The decision as to
the correct surgical approach, that is, LAR or APR, is
sometimes extremely difficult for some patients with rectal
cancer close to but not involving the sphincter. In these
circumstances, there may understandably be a significant
amount of emotional pressure on both the patient and the
clinician to favor a restorative resection over a permanent
stoma. The findings of this study, which showed that
patients with low rectal cancer after APR have an equivalent
general QOL to LAR patients over the long term, may help
preoperatively counsel patients for whom the decision to
perform APR has been made. Further, the findings may also
foster more rational treatment decisions that are guided
predominantly by expectations of oncologic outcomes both
pre-and intraoperatively by clinicians, when they are faced
with ambivalence as to the preferential approach for
patients with ultra-low-lying rectal cancer.
CONCLUSION
Patients undergoing APR for low rectal cancer have
similar long-term overall QOL as those undergoing restora-
tive resection. These findings will help counsel patients with
low rectal cancers, who are being considered for APR.
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